Webinar: Highlights from the 24th Annual Southwest Prostate Cancer Symposium 2019

Co-chaired by Nelson N. Stone, MD and Richard G. Stock, MD, the Southwest Prostate Cancer Symposium™ (SPCS) has been held in Scottsdale, AZ for 23 years. Formerly called the Scottsdale Prostate Cancer Symposium, this multi-day conference is intended for urologists, radiation oncologists, medical oncologists, physicists, and other healthcare professionals involved in the treatment of prostate cancer. It will educate the attendees about advances in management of localized and advanced prostate cancer with a focus on imaging, technology, and training in the related devices.

The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, physicists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

Internationally recognized experts in the management of prostate cancer will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

Diagnostic discussion topics will include genetic markers, prostate pathology, screening, advanced and emerging imaging technologies, and biopsy technologies. For localized disease treatment, this conference will cover active surveillance, hormone therapy, focal therapy, surgical approaches, and the role of testosterone in prostate cancer. Lastly, SPCS 24 will discuss topics regarding the treatment of advanced, metastatic, and castration-resistant prostate cancer.

Target Audience

This activity is designed for and will benefit urologists, radiation oncologists, medical oncologists, physicists, and other health care professionals. It will educate the attendees about advances in management of localized and advanced prostate cancer.

 

Learning Objectives

  • Determine which prostate cancer patients might benefit from active surveillance rather than definitive treatment
  • Determine which prostate cancer patients might benefit from active surveillance rather than definitive treatment
  • Discuss the role of hormone therapy combined with chemotherapy in metastatic disease
  • Describe technical advances, including robotic radical prostatectomy, image-guided external beam radiotherapy (IGRT), proton beam therapy, hypofractionated radiotherapy (SBRT), computer-guided brachytherapy, and mpMRI, and demonstrate their role in     prostate cancer treatment and detection
  • Identify appropriate patients for radiation-based treatments such as brachytherapy IMRT/IGRT, proton therapy robotic and open prostatectomy, and focal therapy taking serum and genetic influences into account
Additional information

CME Coordinator Contact Information

Name: 
Amy Collier
Phone Number: 
+1 (434) 989-9664
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
06/01/2019
Course expires: 
06/01/2020
Cost:
$0.00

 

 

+1 (800) 344-4758

 

 

 

PROGRAM CO-CHAIRS:
Nelson N. Stone, MD, Professor of Urology and Radiation Oncology, Icahn School of Medicine at Mount Sinai, CEO and President of 3D Biopsy, Inc., New York, New York

Richard G. Stock, MD, Professor of Radiation Oncology, Director of Genito-Urinary Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York

 

FACULTY SPEAKERS:

E. David Crawford, MD, University of Colorado, Denver, Aurora, CO

M. Scott Lucia, MD, University of Colorado, Denver

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT

John F. Ward, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, TX

Jason A. Efstathiou, MD, Dphil, Massachusetts General Hospital, Boston, MA

Leonard S. Marks, M.D., David Geffen School of Medicine at UCLA, Los Angeles, CA

Patrick W. McLaughlin, M.D., University of Michigan School of Medicine, Ann Arbor, MI

Abrahams Morgentaler, M.D., Harvard Medical School, Boston, MA

William K. Oh, M.D., The Tisch Cancer Institute, New York, NY

Michael J. Zelefsky, M.D., Weill-Cornell Medical School, New York, NY

 

Disclosure of Conflicts of Interest
It is the policy of Medical College of Wisconsin to insure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MCW identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MCW to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

CJP Medical Communications Disclosure
The employees of CJP Medical Communications have no financial relationships to disclose.

Off-label/Investigational Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing, or the program supporters.


Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically, and are encouraged to consult appropriate resources for any product or device mentioned in this program.

 

ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
06/01/2019
Course expires: 
06/01/2020

Price

Cost:
$0.00
Please login or register to take this course.